Reports Q1 revenue $4.87M, consensus $4.54M. Dana Brown, president and CEO of iCAD (ICAD) commented, “We saw meaningful progress this quarter with increasing adoption of our cloud-based solutions and steady demand for our ProFound Breast Health Suite bringing total annual recurring revenue (TARR) to $10.7 million, supported by 19 new cloud deals. While year-over-year consolidated revenue decreased slightly due to the anticipated revenue recognition shift associated with our SaaS transition, we achieved improved gross margin of 86% compared to 83%, driven by higher-margin cloud revenues, and reduced operating expenses by 4%.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ICAD:
- iCAD collaborates with Microsoft to provide access to mammography solutions
- iCAD downgraded to Neutral from Buy at BTIG
- iCAD downgraded to Hold from Buy at Laidlaw
- iCAD downgraded to Hold from Buy at Craig-Hallum
- Marie Thibault’s Buy Rating on iCAD: Attractive Valuation and Synergistic Potential with RadNet